- Protalix BioTherapeutics Inc PLX has submitted a Type A Meeting request to the FDA regarding PRX-102 Complete Response Letter it received in April.
- The FDA issued the response letter for pegunigalsidase alfa (PRX-102) in Fabry disease, though no reasons were cited in the letter.
- The Type A Meeting is expected to occur within 30 days of the FDA's receipt of the meeting request.
- Price Action: PLX shares are up 4.63% at $1.58 during the premarket session on the last check Monday.
- Related content: Benzinga's Full FDA Calendar.
Loading...
Loading...
PLXProtalix BioTherapeutics Inc
$1.37-2.15%
Edge Rankings
Momentum
49.40
Growth
Not Available
Quality
Not Available
Value
67.81
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
